Biotech Values

[mcbio]

GLPG/ABBV -

I personally expect Abbvie to license it I see this as a very small investment to make even if their JAK compares favorably (I am guessing it does not but don't have much to go on besides vaguely recalling GLPG management mentioning seeing some preclinical data on Abbvie's JAK in much earlier CC's) it takes risk/competition away.

FWIW, I agree completely with you here. Would be a bit of a surprise to me if they don't license filgotinib for this very reason.

I thought the data especially for ACR-70 were particularly strong. Further there is more data on male 200mg dosing to possibly remove that restriction in Phase 3 (note this was in the US only). My main concern when I first saw results was the patient death. Its not clear what if any role filgotinib had nor apparently will it likely ever be known. But apparently the DSMB was not concerned enough to intervene and the company said no other deaths have occurred in any trial (including Chrohn's).

What odds do you give the pending Crohn's data being positive? That's another potential big catalyst I would think.

I thought the pre-clinical IPF drug sounded promising but then I saw that Janssen returned full rights even before seeing the potential clinical PoC data I think and without any kind of explanation in the GLPG PR (such as the customary "it wasn't a strategic fit for our big pharma partner" etc. etc.).